Company Overview and News

Zenith Minerals extends focus to cobalt at Split Rocks project

Zenith Minerals Ltd (ASX:ZNC) has extended its focus on lithium and gold to include cobalt at the Spilt Rocks project in Western Australia.
Upvote Downvote

Zenith Minerals secures funding to unlock U.S., Mexico lithium projects

Zenith Minerals (ASX:ZNC) has entered into a funding deal with a private company controlled by prominent UK investor Jim Mellon to unlock the potential of its U.S. and Mexican lithium projects.
Upvote Downvote

Zenith Minerals to update on lithium projects

Zenith Minerals (ASX:ZNC) has been granted a trading halt by the ASX< with its shares placed in pre-open.
Upvote Downvote

Zenith Minerals concludes successful gold drilling program in Turkey

The latest results from a single drill hole at the Discovery Zone indicates gold mineralisation over a 23.5 metre interval, including 9.4 metres at 1.5 g/t gold and 3.5 metres at 2.1 g/t gold. The Discovery Zone gold mineralisation remains open to the northeast, southwest and is open down dip. These new drill results at the Discovery Zone are located 1.3 kilometres southeast of high-grade, near surface gold intersections previously reported at the Kuzey Zone, which includes: - 3.
Upvote Downvote

Zenith Minerals Ltd to reveal gold results

Zenith Minerals Ltd (ASX:ZNC) has been granted a trading halt by the ASX pending exploration results from the Kavaklitepe gold project, which is located western Turkey. The halt will remain in place until the opening of trade on Wednesday 5th October 2016, or earlier if an announcement is made to the market Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.
Upvote Downvote

Zenith Minerals Ltd to reveal material results

Zenith Minerals Ltd (ASX:ZNC) is focused on the exploration and development of base, industrial and precious metal deposits - principally in Australia.
Upvote Downvote

Appendix 3B

Upvote Downvote

Appendix 3B

Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...